New drug combo shows promise in shrinking esophageal tumors before surgery
NCT ID NCT07385001
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of an immunotherapy drug (ivonescimab) with two chemotherapy drugs before surgery for people with a certain type of advanced esophageal cancer. The goal is to see if this approach can shrink tumors enough to improve long-term outcomes. About 45 adults with resectable, locally advanced esophageal squamous cell carcinoma will participate.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tangdu Hospitial
RECRUITINGXi'an, Shannxi, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new infusion drug shrink Hard-to-Treat tumors?
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a new immunotherapy combo tame aggressive appendiceal cancer?
- Can a new drug rally the immune system against Hard-to-Treat cancers?
- AI biomarker may reveal who responds to esophageal cancer immunotherapy
- Can a new drug shrink Hard-to-Treat adrenal tumors?